With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13708-12-8,5-Methylquinoxaline,as a common compound, the synthetic route is as follows.
Reference Example 74 2-[N-(3-Cyanophenyl)-N-(5-quinoxalinylmethyl)amino]-N-[4-(1-trifluoroacetylpiperidin-4-yl)phenyl]acetamide 5-Methylquinoxaline (710 mg) and 920 mg of N-bromosuccinimide were dissolved in 8 ml of carbon tetrachloride, 50 mg of 2,2′-azobis(isobutyronitrile) was added to the solution, and the mixture was heated under reflux under an argon atmosphere for 5 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in 8 ml of isopropanol. To the solution were added 0.60 ml of N-ethyldiisopropylamine, 418 mg of sodium iodide and 1.0 g of 2-(3-cyanophenylamino)-N-[4-(1-trifluoroacetylpiperidin-4-yl)phenyl]acetamide, and the mixture was heated under reflux for 45 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: ethyl acetate-hexane) to give 560 mg of 2-[N-(3-cyanophenyl)-N-(5-quinoxalinylmethyl)amino]-N-[4-(1-trifluoroacetylpiperidin-4-yl)phenyl]acetamide. 1H-NMR(CDCl3) delta ppm: 1.56-1.72 (2H, m), 1.85-2.00 (2H, m), 2.70-2.93 (2H, m), 3.16-3.30 (1H, m), 4.05-4.17 (1H, m), 4.21 (2H, s), 4.60-4.72 (1H, m), 5.33 (2H, s), 7.00-7.19 (5H, m), 7.23-7.38 (3H, m), 7.53-7.61 (1H, m), 7.70-7.80 (1H, m), 8.05-8.26 (2H, m), 8.80-8.94 (2H, m)
13708-12-8, The synthetic route of 13708-12-8 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Kissei Pharmaceutical Co., Ltd.; EP1020434; (2000); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider